呼吸器疾患検査市場- 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、用途別、エンドユーザー別、地域別、競合別、2020-2030年

呼吸器疾患検査の世界市場規模は、2024年に60億1,000万米ドルとなり、2030年までのCAGRは5.72%で堅調な成長が予測されています。

呼吸器診断薬は、様々な肺疾患を特定し管理するために、肺機能と関連する呼吸プロセスを臨床評価します。これらの診断法は、喘息、慢性閉塞性肺疾患（COPD）、肺がん、気管支炎、肺線維症などの疾患の発見に重要な役割を果たしています。呼吸器診断には、機械的検査、画像検査、分子検査などのアプローチを含む広範なツールと技術が使用されています。一般的な手順には、閉塞性肺疾患と拘束性肺疾患を評価するために気流と肺容積を測定するスパイロメトリーや、血中酸素飽和度を評価するオキシメトリーなどがあります。

経皮的二酸化炭素（CO2）モニタリングは、皮膚を通して血液中のCO2濃度を測定するもので、臨床医が呼吸効率を評価するのに役立ちます。もう一つの手法である鼻腔吸気圧（SNIP）は、特に神経筋障害のある患者の吸気筋力を評価するために用いられます。胸部X線やコンピュータ断層撮影（CT）スキャンなどの画像診断法は、肺の構造を可視化し、腫瘍や感染症、線維化を特定し、さらなる介入を導くために極めて重要です。これらの画像診断ツールは、正確な診断と治療計画をサポートする詳細な情報を提供します。特に、日中の疲労、大きないびき、睡眠中の呼吸の中断などの症状を示す患者には、閉塞性睡眠時無呼吸症候群や夜間低換気症などの病態を診断するために睡眠検査が行われます。これらの検査は、睡眠中の呼吸パターン、酸素レベル、その他の生理学的機能をモニターします。呼吸器診断は、肺疾患の早期発見、モニタリング、管理に不可欠です。タイムリーな介入を促進するだけでなく、個々の患者の呼吸プロファイルに基づいた治療戦略の調整にも役立つため、臨床転帰とQOLが改善されます。

主な市場促進要因

呼吸器疾患の負担増

主な市場課題

高コストと熟練専門家の不足

主な市場動向

ポイントオブケア検査（POCT）の拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の呼吸器疾患検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 検査の種類別（画像検査、機械検査、体外診断検査）
  • 用途別（COPD、肺がん、喘息、結核）
  • エンドユーザー別（病院、診断センターなど）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の呼吸器疾患検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の呼吸器疾患検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の呼吸器疾患検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の呼吸器疾患検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの呼吸器疾患検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

第13章 世界の呼吸器疾患検査市場：SWOT分析

第14章 競合情勢

• Beckton Dickinson and Company
• Koninklijke Philips N.V.
• ResMed Inc.
• Medtronic PLC
• Carestream Health Inc.
• MG Diagnostic Corporation
• Abbott Laboratories Ltd.
• ThermoFisher Scientific Inc.
• Biomerieux Inc.
• QIAGEN NV

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Respiratory Disease Testing Market was valued at USD 6.01 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 5.72% through 2030F. Respiratory diagnostics involve the clinical assessment of lung function and related respiratory processes to identify and manage various pulmonary conditions. These diagnostics play a vital role in detecting disorders such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, bronchitis, and pulmonary fibrosis.A broad spectrum of tools and techniques is used in respiratory diagnostics, encompassing mechanical, imaging, and molecular testing approaches. Common procedures include spirometry, which measures airflow and lung volumes to assess obstructive and restrictive lung diseases, and oximetry, which evaluates blood oxygen saturation levels.

Transcutaneous carbon dioxide (CO2) monitoring is used to measure CO2 levels in the blood through the skin, helping clinicians assess respiratory efficiency. Another technique, sniff nasal inspiratory pressure (SNIP), is employed to evaluate inspiratory muscle strength, especially in patients with neuromuscular disorders. Imaging methods such as chest X-rays and computed tomography (CT) scans are crucial for visualizing lung structure, identifying tumors, infections, or fibrosis, and guiding further interventions. These imaging tools provide detailed information that supports accurate diagnosis and treatment planning. In specific cases, sleep studies are conducted to diagnose conditions like obstructive sleep apnea and nocturnal hypoventilation, especially in patients exhibiting symptoms such as daytime fatigue, loud snoring, or interrupted breathing during sleep. These studies monitor breathing patterns, oxygen levels, and other physiological functions during sleep. The respiratory diagnostics are essential for early detection, monitoring, and management of pulmonary diseases. They not only facilitate timely intervention but also help in tailoring treatment strategies based on the individual patient's respiratory profile, thereby improving clinical outcomes and quality of life.

Key Market Drivers

Growing Burden of Respiratory Diseases

The increasing prevalence of respiratory diseases is a significant driver for market growth. For instance, according to a 2023 article, Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition linked to serious complications such as cardiovascular disease, respiratory failure, and lung cancer. Key risk factors include smoking, air pollution (indoor and outdoor), genetic predisposition, occupational exposures, and infections during childhood or adulthood. Factors such as the rise in smokers, alcohol consumption, sedentary lifestyle habits, and stressful routines have led to an increase in cases of COPD and other severe respiratory conditions, including lung cancer. The technological advancements in respiratory diagnostic testing, such as the utilization of Internet of Things (IoT) and Artificial Intelligence (AI) for COPD diagnosis and outpatient management, have positively impacted market growth. The growing demand for respiratory diagnostics devices in privately-owned hospitals and healthcare centers, along with the efforts of government and non-governmental organizations (NGOs) to improve access to quality healthcare facilities, are key drivers of the respiratory diagnostics market. Respiratory symptoms rank among the primary reasons for seeking medical consultation in primary healthcare centers. Key preventable chronic respiratory disorders include asthma, COPD, allergic rhinitis, sleep apnea, and tuberculosis (particularly multi-drug resistant tuberculosis). As of September 2022, the CDC reported 873,000 emergency department visits for COPD in the United States in 2020, with 5% of adults receiving a new diagnosis of COPD, emphysema, or chronic bronchitis. These statistics underscore the growing burden of respiratory diseases on society, which is expected to drive the demand for respiratory disease testing and fuel market growth.

Key Market Challenges

High Cost and Lack of Skilled Professionals

The significant cost associated with diagnostic procedures poses a major challenge to the growth of the global respiratory diagnostics market during the forecast period. The rapid technological advancements in the field have led to a shortage of qualified specialists. The lack of competent experts has greatly hindered the proper handling of instruments and the execution of procedures. The cost associated with setting up and maintaining advanced respiratory disease testing facilities, including purchasing equipment, reagents, and maintaining quality control, can be substantial. This cost burden can discourage healthcare providers from investing in the necessary infrastructure. The high cost of establishing and operating testing facilities can lead to geographic disparities in access. Remote or underserved areas may lack the resources needed to offer comprehensive respiratory disease testing, limiting access for vulnerable populations. The specialized nature of respiratory disease testing requires trained and skilled laboratory professionals who can operate and interpret complex diagnostic equipment accurately. A shortage of such professionals can lead to delays in testing, misinterpretation of results, and overall reduced testing capacity.

Key Market Trends

Point-of-Care Testing (POCT) Expansion

The expansion of point-of-care testing for respiratory diseases will enable rapid and convenient testing in various healthcare settings, such as clinics, pharmacies, and community health centers. POCT devices will facilitate timely diagnosis and monitoring, especially in resource-limited environments. POCT devices provide rapid results, often within minutes, allowing healthcare providers to make timely decisions about patient care. In cases of acute respiratory conditions, such as respiratory infections or exacerbations of chronic diseases, quick diagnosis can lead to immediate initiation of appropriate treatment. Traditional laboratory testing involves transporting samples, processing, and result reporting, which can lead to delays.

POCT devices minimize turnaround time, enabling healthcare providers to quickly assess a patient's respiratory status and make informed decisions without waiting for external laboratory results. As technology continues to advance, the development of accurate, user-friendly, and affordable POCT devices for respiratory diseases has the potential to revolutionize healthcare delivery, particularly in settings where access to traditional laboratory testing is limited. It empowers healthcare providers with actionable information and empowers patients to actively manage their respiratory health, contributing to better overall healthcare outcomes.

Key Market Players

• Beckton Dickinson and Company
• Koninklijke Philips N.V.
• ResMed Inc.
• Medtronic PLC
• Carestream Health Inc.
• MG Diagnostic Corporation
• Abbott Laboratories Ltd.
• ThermoFisher Scientific Inc.
• Biomerieux Inc.
• QIAGEN NV

Report Scope:

In this report, the Global Respiratory Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Disease Testing Market, By Test Type:

• Imaging Tests
• Mechanical Tests
• In-vitro Diagnostic Tests

Respiratory Disease Testing Market, By Application:

• COPD
• Lung Cancer
• Asthma
• Tuberculosis

Respiratory Disease Testing Market, By End User:

• Hospitals
• Diagnostic Centres
• Others

Respiratory Disease Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Disease Testing Market.

Available Customizations:

Global Respiratory Disease Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Disease Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests)
  • 5.2.2. By Application (COPD, Lung Cancer, Asthma, Tuberculosis)
  • 5.2.3. By End User (Hospitals, Diagnostic Centers, and Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Respiratory Disease Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Respiratory Disease Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Respiratory Disease Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Respiratory Disease Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Respiratory Disease Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Respiratory Disease Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Respiratory Disease Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Respiratory Disease Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Respiratory Disease Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Respiratory Disease Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Respiratory Disease Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Respiratory Disease Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Respiratory Disease Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Respiratory Disease Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Respiratory Disease Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Respiratory Disease Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Respiratory Disease Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Respiratory Disease Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Respiratory Disease Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Respiratory Disease Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Respiratory Disease Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Respiratory Disease Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Respiratory Disease Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Respiratory Disease Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Global Respiratory Disease Testing Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Beckton Dickinson and Company
  • 14.1.1. Business Overview
  • 14.1.2. Services Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. Koninklijke Philips N.V.
• 14.3. ResMed Inc.
• 14.4. Medtronic PLC
• 14.5. Carestream Health Inc.
• 14.6. MG Diagnostic Corporation
• 14.7. Abbott Laboratories Ltd.
• 14.8. ThermoFisher Scientific Inc.
• 14.9. Biomerieux Inc.
• 14.10. QIAGEN NV

15. Strategic Recommendations

16. About Us & Disclaimer